Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.

Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB

Open source

DOI: 10.1158/1078-0432.ccr-21-1656
Published: 2021 Dec 1
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-21-1656,
  title = {Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.},
  author = {Westin SN and Labrie M and Litton JK and Blucher A and Fang Y and Vellano CP and Marszalek JR and Feng N and Ma X and Creason A and Fellman B and Yuan Y and Lee S and Kim TB and Liu J and Chelariu-Raicu A and Chen TH and Kabil N and Soliman PT and Frumovitz M and Schmeler KM and Jazaeri A and Lu KH and Murthy R and Meyer LA and Sun CC and Sood AK and Coleman RL and Mills GB},
  year = {2021},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-21-1656},
  url = {https://doi.org/10.1158/1078-0432.ccr-21-1656}
}

RIS

TY  - JOUR
TI  - Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.
AU  - Westin SN
AU  - Labrie M
AU  - Litton JK
AU  - Blucher A
AU  - Fang Y
AU  - Vellano CP
AU  - Marszalek JR
AU  - Feng N
AU  - Ma X
AU  - Creason A
AU  - Fellman B
AU  - Yuan Y
AU  - Lee S
AU  - Kim TB
AU  - Liu J
AU  - Chelariu-Raicu A
AU  - Chen TH
AU  - Kabil N
AU  - Soliman PT
AU  - Frumovitz M
AU  - Schmeler KM
AU  - Jazaeri A
AU  - Lu KH
AU  - Murthy R
AU  - Meyer LA
AU  - Sun CC
AU  - Sood AK
AU  - Coleman RL
AU  - Mills GB
PY  - 2021
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-21-1656
UR  - https://doi.org/10.1158/1078-0432.ccr-21-1656
ER  -

APA

SN, W., M, L., JK, L., A, B., Y, F., CP, V., JR, M., N, F., X, M., A, C., B, F., Y, Y., S, L., TB, K., J, L., A, C., TH, C., N, K., PT, S., M, F., KM, S., A, J., KH, L., R, M., LA, M., CC, S., AK, S., RL, C., & GB, M. (2021). Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-1656

Source records

pubmed · retrieved 2026-09-26T18:06:52.436Z